Therapy for Nonmetastatic Castration-Resistant Prostate Cancer

Nicholas J. Vogelzang, MD


March 12, 2021

The SPARTAN, PROSPER, and ARAMIS trials led to the FDA approval of the nonsteroidal antiandrogen agents apalutamide, enzalutamide, and darolutamide for nonmetastatic castration-resistant prostate cancer. These pivotal studies demonstrated that each of these therapies can significantly improve overall survival for patients with this disease.

In this ReCAP, Dr Nicholas J. Vogelzang, of the University of Nevada School of Medicine, discusses important similarities and differences among the studies. He compares the reduction in death rates, taking into account differences in study design, and reviews notable differences in drug toxicities.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.